LEO Pharma strengthens Board of Directors

LEO Pharma expands its Board of Directors with Jesper Hoiland, EVP Novo Nordisk US. LEO Pharma is now in an even stronger position to drive growth in the US – the world’s biggest pharma market.  

LEO Pharma has elected Jesper Hoiland, Executive Vice President of Novo Nordisk US, as new member of its Board of Directors. Jesper Hoiland’s extensive experience from the international pharma sector and from his current position leading Novo Nordisk in the US strengthens LEO Pharma’s growth plans. Not least in the US which remains a key market for LEO Pharma.  
 
“Jesper Hoiland has unique experience in developing a Danish pharma company to become a global leader in its market. His competences and experience will make a valuable contribution towards LEO Pharma’s future development and towards realising our vision of becoming the preferred dermatology care partner, improving people’s lives around the world,” says Jukka Pertola, Chairman of the Board of Directors at LEO Pharma. 
 
30 years specialised experience 
 
Jesper Hoiland joined Novo Nordisk in 1987 and has held several senior leadership positions during his nearly 30-year career with the company. He has held positions as Managing Director for Novo Nordisk Australia, SVP for International Marketing, SVP for International Operations and SVP for Novo Nordisk North America – and since April 2015 as EVP with responsibility for the US market. He sees clear similarities between Novo Nordisk and LEO Pharma. 
 
“LEO Pharma has significant potential for global growth in a specialised market. The company’s strategic direction and opportunities ahead are in many ways very similar to the journey I have been part of at Novo Nordisk. I truly look forward to contributing to LEO Pharma’s continued growth journey – not least with the hands-on experience I have from the world’s biggest pharma market,” says Jesper Hoiland.